STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
But some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy.
- … The Trump administration is pulling the nomination of Heidi Overton to lead the U.S.
- Bill Cassidy (R-La.), said on Tuesday that Overton had enough support to clear his committee and win confirmation.
- Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate, STAT notes.
An independent monitoring committee reached that conclusion after reviewing results from a late-stage study and Merck said its review of the full data confirmed the finding.
- Congratulations on making it this far, and remember there are only a few more days until the weekend arrives.
- The Senate’s health panel had been expected to vote on her nomination Wednesday, and the panel’s leader, Sen.
- The decision ends a broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials.
- Continue to STAT+ to read the full story….
- Nemtabrutinib is an oral drug designed to block BTK, a protein that helps cancerous B cells grow.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →